0.5750GBp0.00%Mkt Cap: 3.95M GBpP/E: —Last update: 2026-05-13
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B158.33
P/S559.49
EV/EBITDA—
EV/Revenue143.19
EPS (TTM)0.00
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-17.84%
FCF Margin-9983.94%
Operating CF-971.50K GBp
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-1.73M GBp
Technical
SMA 500.4895 (+17.5%)
SMA 2000.5101 (+12.7%)
Beta0.29
S&P 52W Chg24.23%
Avg Vol (30d)1.78M
Avg Vol (10d)193.08K
Technical Indicators
RSI (14)62.5
MACD0.0184
MACD Signal0.0217
MACD Hist.-0.0033
BB Upper0.6314 GBp
BB Middle0.5825 GBp
BB Lower0.5336 GBp
BB Width16.80%
ATR (14)0.0550 GBp
Vol Ratio (20d)1.40x
52W Range
0.350035% of range1.000
52W High1.000 GBp
52W Low0.3500 GBp
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-14537.52%
Oper. Margin-12742.98%
ROE-163.46%
ROA-136.46%
Revenue Growth-5.50%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio23.55
Quick Ratio23.55
Book Value/Sh0.0030 GBp
Cash/Share0.0030 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 19, 1997
Pay Date—
Splits
Last Split200:800
Split DateMay 3, 2017
Ownership
Shares Out.832.28M
Float358.34M
Insiders37.84%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap3.95M GBp
Enterprise Value1.01M GBp
Revenue (TTM)7.07K GBp
Gross Profit7.28K GBp
Net Income (TTM)-1.06M GBp
Revenue/Share0.0000 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees4
Last Price0.5750 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—